dr. jonasch on the potential of immunotherapy for sarcomatoid rcc
Published 7 years ago • 189 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
1:14
dr. jonasch on single-agent pembrolizumab in non-clear cell rcc
-
1:19
dr. clark on the potential of immunotherapy in renal cell carcinoma
-
1:04
dr. jonasch on first- and second-line options for patients with rcc
-
1:04
dr. jonasch on modulating the tumor microenvironment in rcc
-
1:11
dr. motzer on the milestone of immunotherapy in rcc
-
1:40
dr. jonasch on using the tumor microenvironment and epigenetics as biomarkers in rcc
-
1:10
dr. jonasch on molecular understanding of clear cell rcc
-
29:37
dr gengwen tian, nkt trial update & new immunotherapy trial opening
-
0:54
dr. jonasch on promise of immuno-oncology agents in rcc
-
1:05
dr. pal on potential tivozanib-based combinations in rcc
-
0:27
eric jonasch, md, on integrating immunotherapies into renal cell carcinoma treatment algorithms
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
0:58
eric jonasch, md, on which non-metastatic renal cell cancer patients should receive adjuvant therapy
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
0:53
dr. chowdhury on sequencing of immunotherapy regimens for rcc
-
1:02
dr. sznol on immunotherapy in patients with rcc
-
7:05
upfront immunotherapy for metastatic kidney cancer
-
4:14
molecular determinants of ici response in sarcomatoid and rhabdoid rcc | ziad bakouny
-
4:49
potential prognostic markers in sarcomatoid and rhabdoid rcc